New combo therapy aims to calm rogue immune cells in stubborn blood disorders
NCT ID NCT07574073
First seen May 08, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can better control immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) that haven't responded to other treatments. The drugs work together to stop the immune system from attacking the body's own blood cells. The study will enroll 30 adults and measure how many patients achieve a response at 6 months, while also monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.